Cargando…
Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320583/ https://www.ncbi.nlm.nih.gov/pubmed/25523155 http://dx.doi.org/10.1186/1471-2407-14-981 |
_version_ | 1782356147139772416 |
---|---|
author | Lamm, Wolfgang Natter, Camilla Schur, Sophie Köstler, Wolfgang J Reinthaller, Alexander Krainer, Michael Grimm, Christoph Horvath, Reinhard Amann, Gabriele Funovics, Philipp Brodowicz, Thomas Polterauer, Stephan |
author_facet | Lamm, Wolfgang Natter, Camilla Schur, Sophie Köstler, Wolfgang J Reinthaller, Alexander Krainer, Michael Grimm, Christoph Horvath, Reinhard Amann, Gabriele Funovics, Philipp Brodowicz, Thomas Polterauer, Stephan |
author_sort | Lamm, Wolfgang |
collection | PubMed |
description | BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. METHODS: Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. RESULTS: Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS, respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in terms of OS (p < 0.0001). CONCLUSION: At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological tumor behavior. |
format | Online Article Text |
id | pubmed-4320583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43205832015-02-08 Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma Lamm, Wolfgang Natter, Camilla Schur, Sophie Köstler, Wolfgang J Reinthaller, Alexander Krainer, Michael Grimm, Christoph Horvath, Reinhard Amann, Gabriele Funovics, Philipp Brodowicz, Thomas Polterauer, Stephan BMC Cancer Research Article BACKGROUND: Leiomyosarcomas represent the largest subtype of soft tissue sarcomas. Two subgroups can be distinguished, non-uterine (NULMS) and uterine leiomyosarcomas (ULMS). The aim of this retrospective study was to evaluate differences in clinical features and outcome between these two subgroups. METHODS: Outcome and clinical-pathological parameters between 50 patients with NULMS and 45 patients with ULMS were assessed, and compared between both groups. Univariate and multivariable survival analyses were performed. RESULTS: Patients with ULMS presented with larger tumors when compared to patients with NULMS (p < 0.001). More patients with ULMS initially presented with metastatic disease (67% vs. 36%, p = 0.007). Most common metastatic site was lung for both subtypes (28% and 38%). Five-year overall survival (OS) rates of 82.6% and 41.2% and median OS times of 92.6 (range: 79.7-105.4) and 50.4 (range: 34.8-66.0) months were observed in patients with NULMS and ULMS, respectively (p = 0.006). In multivariate analysis, initial metastatic disease remained an independent prognostic factor in terms of OS (p < 0.0001). CONCLUSION: At time of diagnosis ULMS were larger and more often metastasized. Therefore patients with ULMS showed unfavorable outcome when compared to NULMS. Later diagnosis might be caused by differences in symptoms and clinical presentation or a more aggressive biological tumor behavior. BioMed Central 2014-12-18 /pmc/articles/PMC4320583/ /pubmed/25523155 http://dx.doi.org/10.1186/1471-2407-14-981 Text en © Lamm et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lamm, Wolfgang Natter, Camilla Schur, Sophie Köstler, Wolfgang J Reinthaller, Alexander Krainer, Michael Grimm, Christoph Horvath, Reinhard Amann, Gabriele Funovics, Philipp Brodowicz, Thomas Polterauer, Stephan Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title | Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title_full | Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title_fullStr | Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title_full_unstemmed | Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title_short | Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
title_sort | distinctive outcome in patients with non-uterine and uterine leiomyosarcoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320583/ https://www.ncbi.nlm.nih.gov/pubmed/25523155 http://dx.doi.org/10.1186/1471-2407-14-981 |
work_keys_str_mv | AT lammwolfgang distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT nattercamilla distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT schursophie distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT kostlerwolfgangj distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT reinthalleralexander distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT krainermichael distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT grimmchristoph distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT horvathreinhard distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT amanngabriele distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT funovicsphilipp distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT brodowiczthomas distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma AT polterauerstephan distinctiveoutcomeinpatientswithnonuterineanduterineleiomyosarcoma |